Arena Pharmaceuticals reports positive study results

Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from a Phase 2 OASIS trial for etrasimod to treat ulcerative colitis. Shares of the biopharmaceutical leaped $8.86 to close at $39.75.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.